Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…
News
Changes in the properties of endothelial cells that line blood vessels may underlie increases in the numbers of circulating immune neutrophils in people with hereditary angioedema (HAE), according to a recent report. Although neutrophils are more abundant and activated in the blood of people with HAE types 1 and…
Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…
Adarx Pharmaceuticals will use $200 million in oversubscribed Series C financing to further develop its clinical programs — including ADX-324, its treatment candidate for hereditary angioedema (HAE) — the clinical-stage biotechnology company announced. The funding round was led by Bain Capital Life Sciences and TCGX, an investment firm…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…
Pharvaris has completed patient enrollment for its proof-of-concept CHAPTER-1 clinical trial that will evaluate the safety and effectiveness of deucrictibant as a prophylactic, or preventive, treatment for adults with hereditary angioedema (HAE). While the global Phase 2 CHAPTER-1 study (NCT05047185) is still on hold in the U.S.,…
Enrollment for the Phase 2 portion of a clinical trial testing NTLA-2002, Intellia Therapeutics’ experimental gene-editing therapy for hereditary angioedema (HAE), is expected to be completed this year. This is the result of “substantial interest from physicians and patients to participate in the NTLA-2002 clinical program,” the company…
Treatment with tranexamic acid may ease symptoms and prevent intubation in people who develop angioedema after receiving certain high blood pressure medications called angiotensin-converting enzyme (ACE) inhibitors, a review of published studies shows. The findings also suggest tranexamic acid may be more advantageous than other therapies currently used to…
A 26-year-old woman developed a rare case of non-episodic angioedema associated with eosinophilia (NEAE) following her second dose of the Pfizer-BioNTech COVID-19 vaccine, according to a study from Japan. Eosinophilia refers to higher-than-normal levels of a type of immune cells called eosinophils. Her NEAE symptoms were resolved completely two months…
The use of Dupixent (dupilumab), an approved treatment for skin and respiratory conditions linked to a specific type of inflammation, led to the development of angioedema in a woman in her 40s, as described in a new case report from U.S. researchers. The woman, who had a type…
Recent Posts
- Body stress signals in HAE match those of autoimmune disorder ITP
- Biocryst expands HAE treatment portfolio with Astria acquisition
- When executing a plan, each person must do the right job at the right time
- Blood pressure drug lisinopril causes gut swelling in man, 54, in rare case
- Rare Disease Week is an opportunity to show that rare is not invisible